Lantheus (LNTH) AI Stock Analysis

• Market Cap: $3.50B
• Dividend Yield: N/A
• Average Volume (3M): 1.47M
• Price to Earnings (P/E): 22.2
• Beta (1Y): 0.58
• Revenue Growth: 1.95%
• EPS Growth: -60.40%
• Country: US
• Employees: 808
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 1.27
• Shares Outstanding: 66,311,775
• 10 Day Avg. Volume: 1,500,435
• 30 Day Avg. Volume: 1,468,003
• PEG Ratio: -3.52
• Price to Book (P/B): 5.69
• Price to Sales (P/S): 4.04
• P/FCF Ratio: 12.55
• Enterprise Value/Market Cap: 1.06
• Enterprise Value/Revenue: 2.43
• Enterprise Value/Gross Profit: 3.90
• Enterprise Value/Ebitda: 11.34
• 1Y Price Target: $76.83
• Price Target Upside: 43.37% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 7
• EPS Forecast (FY): 5.59
• Revenue Forecast (FY): $1.50B

• Rating: 69 Neutral
• Price Target: $59.00 ▲(10.10% Upside)

Lantheus shows strong financial performance and strategic growth initiatives, particularly in Alzheimer's imaging. However, technical indicators suggest bearish momentum, and challenges in PYLARIFY sales and gross margins pose risks. The stock is reasonably valued, but the absence of a dividend yield may deter some investors.

Positive Factors

Strategic Acquisitions

These acquisitions diversify revenue streams and expand capabilities across the radiopharmaceutical value chain, enhancing long-term growth potential.

Neurology Franchise Growth

Expansion of Neuraceq supports growth due to rising Alzheimer's prevalence, strengthening Lantheus's position in the neurology market.

Free Cash Flow Growth

Strong free cash flow growth indicates robust financial health and efficient earnings conversion, supporting future investments and stability.

Negative Factors

PYLARIFY Sales Decline

Declining PYLARIFY sales due to increased competition and pricing pressures could impact revenue growth and market share if not addressed.

Gross Profit Margin Pressure

Sustained margin pressure from pricing impacts and cost structure changes could affect profitability and operational efficiency long-term.

Operating Income Decline

A significant decline in operating income due to increased expenses and investments may strain financial resources and limit future growth.

Lantheus Business Overview & Revenue Model

Company Description

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.

How the Company Makes Money

Lantheus generates revenue primarily through the sale of its diagnostic imaging agents and radiopharmaceuticals. The company's revenue model is based on direct sales to hospitals, imaging centers, and other healthcare providers. Key revenue streams include the sales of Pylarify and other established imaging products, as well as potential royalties from partnerships and collaborations with other pharmaceutical companies. Significant partnerships, such as agreements with healthcare institutions and alliances with research organizations, enhance its market reach and contribute to the company's earnings. Additionally, Lantheus may benefit from expanding its product pipeline through research and development, leading to new launches that can further increase revenue.

Lantheus Financial Statement Overview

Summary

Lantheus demonstrates strong financial performance with significant revenue growth and solid profitability. The balance sheet shows improved leverage and strong equity returns, though high debt levels pose a risk. Cash flow generation is robust, but the decline in free cash flow warrants attention. Overall, the company is well-positioned in its industry, with potential for continued growth.

Income Statement

Lantheus shows strong revenue growth with a TTM growth rate of 34.7%, indicating robust demand for its products. The gross profit margin is healthy at 63.7%, and the net profit margin of 17.8% reflects solid profitability. However, there is a slight decline in margins compared to the previous year, suggesting some cost pressures.

Balance Sheet

The company's debt-to-equity ratio has improved to 0.53, indicating better leverage management. Return on equity is strong at 23.6%, showcasing effective use of equity capital. The equity ratio stands at 49.2%, reflecting a balanced capital structure. However, the high total debt remains a potential risk.

Cash Flow

Operating cash flow remains strong with a coverage ratio of 1.88, indicating good cash generation relative to net income. However, free cash flow has declined by 12.5% in the TTM, which could impact future investments. The free cash flow to net income ratio is healthy at 89.7%, suggesting efficient cash conversion.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.53B	1.53B	1.30B	935.06M	425.21M	339.41M
Gross Profit	949.62M	988.29M	709.54M	581.70M	187.69M	138.76M
EBITDA	326.91M	515.27M	491.00M	81.83M	-25.00M	22.69M
Net Income	167.68M	312.44M	326.66M	28.07M	-71.28M	-13.47M
Balance Sheet
Total Assets	2.28B	1.98B	1.65B	1.32B	863.78M	869.82M
Cash, Cash Equivalents and Short-Term Investments	382.01M	912.81M	713.66M	415.65M	98.51M	79.61M
Total Debt	619.44M	619.44M	616.95M	583.51M	191.31M	235.90M
Total Liabilities	1.16B	892.33M	835.26M	874.11M	399.35M	355.62M
Stockholders Equity	1.12B	1.09B	815.89M	447.15M	464.44M	514.21M
Cash Flow
Free Cash Flow	406.28M	493.13M	258.70M	263.43M	41.78M	3.92M
Operating Cash Flow	455.36M	544.75M	305.26M	281.78M	53.92M	16.40M
Investing Cash Flow	-622.26M	-226.01M	5.94M	-276.55M	3.68M	-4.91M
Financing Cash Flow	-317.13M	-118.54M	-13.06M	311.69M	-39.33M	-21.86M

Lantheus Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 53.59
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LNTH, the sentiment is Neutral. The current price of 53.59 is below the 20-day moving average (MA) of 54.71, below the 50-day MA of 53.83, and below the 200-day MA of 74.65, indicating a bearish trend. The MACD of -0.59 indicates Positive momentum. The RSI at 47.70 is Neutral, neither overbought nor oversold. The STOCH value of 46.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for LNTH.

Lantheus Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LNTH	69 Neutral	$3.50B	22.17	14.59%	―	1.95%	-60.40%
ANIP	64 Neutral	$1.80B	49.26	7.83%	―	48.87%	―
AMRX	63 Neutral	$3.56B	788.19	―	―	9.50%	―
SUPN	55 Neutral	$2.62B	―	-1.86%	―	4.54%	-130.59%
HCM	52 Neutral	$2.73B	5.76	47.54%	―	-1.35%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PRGO	50 Neutral	$2.78B	―	-0.65%	5.55%	-2.55%	66.00%

Lantheus Corporate Events

Lantheus Holdings Reports Q3 2025 Earnings and Strategic Updates

Lantheus Holdings Inc., a leading company in the radiopharmaceutical sector, focuses on providing innovative solutions for disease detection and management to enhance patient outcomes. In its third quarter of 2025, Lantheus reported a worldwide revenue of $384 million, with a significant focus on strategic diversification and leadership transition. The company experienced a slight revenue increase of 1.4% compared to the previous year, despite a notable decline in GAAP net income by 78.8%. Adjusted earnings per share also decreased by 25.3% year-over-year, reflecting the challenges and strategic investments made during the quarter. Key highlights include the completion of the Life Molecular Imaging acquisition, which is expected to bolster Lantheus’ growth and commercial portfolio. Additionally, the company announced several PDUFA dates for its new imaging agents, indicating a robust pipeline and future potential. Looking forward, Lantheus remains optimistic about its strategic initiatives and leadership changes, with a focus on maintaining its market position and advancing its product offerings in the radiopharmaceutical industry.

Lantheus Announces CEO Retirement and Leadership Transition

On November 6, 2025, Lantheus announced a leadership transition with CEO Brian Markison retiring effective December 31, 2025, and Mary Anne Heino appointed as Executive Chair and Interim CEO. The company reported third-quarter 2025 financial results, including a revenue of $384 million and a decrease in net income, while also highlighting strategic initiatives such as the acquisition of Life Molecular Imaging and the advancement of its radiopharmaceutical pipeline.

The most recent analyst rating on (LNTH) stock is a Hold with a $63.00 price target. To see the full list of analyst forecasts on Lantheus stock, see the LNTH Stock Forecast page.

Lantheus CCO Amanda Morgan Takes Leave of Absence

Lantheus Holdings, Inc. announced that Amanda Morgan, the Chief Commercial Officer, will take a leave of absence from the company for personal reasons, effective August 8, 2025.

The most recent analyst rating on (LNTH) stock is a Buy with a $73.00 price target. To see the full list of analyst forecasts on Lantheus stock, see the LNTH Stock Forecast page.

Lantheus Holdings Inc’s Mixed Earnings Call: Challenges and Strategic Advances

Lantheus Holdings Inc’s recent earnings call presented a mixed sentiment, highlighting significant challenges and strategic advancements. While the company faces hurdles in maintaining PYLARIFY’s market share due to pricing pressures, there is optimism surrounding strategic developments in neurology and a new PYLARIFY formulation. Additionally, a robust stock repurchase program underscores confidence in long-term growth and stabilization efforts.

Lantheus Holdings Reports Q2 2025 Results and Strategic Moves

Lantheus Holdings Inc., a leader in the radiopharmaceutical sector, focuses on developing innovative diagnostic and therapeutic products to enhance patient outcomes. In its second quarter of 2025, Lantheus reported worldwide revenue of $378 million, with a GAAP earnings per share of $1.12 and an adjusted earnings per share of $1.57. The company also announced the FDA’s acceptance of a new drug application for a PSMA PET imaging agent and completed the acquisition of Life Molecular Imaging, enhancing its portfolio with the Alzheimer’s diagnostic agent Neuraceq.